Tasocitinib (CP-690,550), an oral Janus kinase inhibitor, significantly improves the symptoms of moderate to severe psoriasis with early onset of efficacy

Authors
Category Primary study
JournalJournal of the American Academy of Dermatology
Year 2011
This article has no abstract
Epistemonikos ID: 8cf7ac85d39be7798a68d97f1db9781e35360d66
First added on: Feb 04, 2025